[go: up one dir, main page]

AR035408A1 - Compuestos derivados de dihidroindol y tetrahidroquinoleina, su empleo, un procedimiento para fabricarlos y composiciones farmaceuticas que los comprenden - Google Patents

Compuestos derivados de dihidroindol y tetrahidroquinoleina, su empleo, un procedimiento para fabricarlos y composiciones farmaceuticas que los comprenden

Info

Publication number
AR035408A1
AR035408A1 ARP010105925A ARP010105925A AR035408A1 AR 035408 A1 AR035408 A1 AR 035408A1 AR P010105925 A ARP010105925 A AR P010105925A AR P010105925 A ARP010105925 A AR P010105925A AR 035408 A1 AR035408 A1 AR 035408A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydroxy
optionally substituted
alkoxy
cycloalkyl
Prior art date
Application number
ARP010105925A
Other languages
English (en)
Inventor
Max Aebi
Jean Ackermann
Alexander Chucholowski
Olivier Morand
Sabine Wallbaum
Thomas Weller
Narendra Panday
Henrietta Dehmlow
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR035408A1 publication Critical patent/AR035408A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de dihidroindol y tetrahidroquinoileína de fórmula (1) en la cual: U es O o un par suelto; V es a) O, s, NR1 o CH2, y L es alquileno inferior o alquenileno inferior; b) es -CH=CH- o -C:::C-, y L es alquileno inferior o un único enlace; W es CO, COO, CONR2, CSO, CSNR2, SO2 o SO2NR2; X es hidrógeno o uno o más sustituyentes halógeno y/o alquilo inferior opcionales; m es 1 o 2; n oscila entre 0 y 7; A1 es hidrógeno, alquenilo inferior, o alquilo inferior opcionalmente sustituido por hidroxi, alcoxi inferior o tio-alcoxi inferior; A2 es cicloalquilo, cicloalquil-alquilo-inferior, alquenilo inferior, alquinilo inferior o alquilo inferior opcionalmente sustituido por hidroxi, alcoxi inferior o tio-alcoxi inferior; A3 y A4 son independientemente uno del otro hidrógeno o alquilo inferior, o A1 y A2 o A1 y A3 están unidos entre sí para formar un anillo y -A1-A2- o -A1-A3- son alquileno inferior o alquenileno inferior opcionalmente sustituido por R3, donde un grupo -CH2- de -A1-A2- o -A1-A3- puede reemplazarse opcionalmente por NR4, S u O; A5 es cicloalquilo, cicloalquilo-alquilo inferior, heterocicloalquilo-alquilo inferior, arilo, arilo-alquilo inferior, heteroarilo, heteroarilo-alquilo inferior, alquilo inferior, opcionalmente sustituido por hidroxi o alcoxi inferior, alquenilo opcionalmente sustituido por hidroxi, o alcadienilo opcionalmente sustituido por hidroxi, R3 es hidroxi, alcoxi inferior, tio-alcoxi inferior, N(R5,R6) o alquilo inferior, opcionalmente sustituido por hidroxi; R1, R2, R4, R5 y R6 son independientemente uno de otro, hidrógeno o alquilo inferior, y sales farmacéuticamente aceptables y/o ésteres farmacéuticamente aceptables de los mismos. Los compuestos son útiles en el tratamiento y/o profilaxis de enfermedades que están asociadas a la 2,3-oxidoescualeno-lanosterol ciclasa, tales como hipercolesterolemia, hiperlipemia, arteriosclerosis, enfermedades vasculares, micosis, infecciones parasitarias, cálculos biliares, tumores y/o alteraciones hiperproliferantes, y/o para el tratamiento y/o profilaxis de tolerancia deteriorada a la glucosa y diabetes. Su empleo, un procedimiento para fabricarlos y composiciones farmacéuticas que los comprenden.
ARP010105925A 2000-12-21 2001-12-20 Compuestos derivados de dihidroindol y tetrahidroquinoleina, su empleo, un procedimiento para fabricarlos y composiciones farmaceuticas que los comprenden AR035408A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00128063 2000-12-21

Publications (1)

Publication Number Publication Date
AR035408A1 true AR035408A1 (es) 2004-05-26

Family

ID=8170751

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105925A AR035408A1 (es) 2000-12-21 2001-12-20 Compuestos derivados de dihidroindol y tetrahidroquinoleina, su empleo, un procedimiento para fabricarlos y composiciones farmaceuticas que los comprenden

Country Status (15)

Country Link
US (2) US6706751B2 (es)
EP (1) EP1358162B1 (es)
JP (1) JP4068459B2 (es)
KR (1) KR100530408B1 (es)
CN (1) CN1208322C (es)
AR (1) AR035408A1 (es)
AT (1) ATE317386T1 (es)
AU (2) AU2002219176B2 (es)
BR (1) BR0116263A (es)
CA (1) CA2431100C (es)
DE (1) DE60117096T2 (es)
ES (1) ES2257381T3 (es)
MX (1) MXPA03005395A (es)
WO (1) WO2002050041A1 (es)
ZA (1) ZA200304646B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
AU2003265681A1 (en) * 2002-08-29 2004-03-19 Merck And Co., Inc. Indoles having anti-diabetic activity
WO2005014755A1 (ja) * 2003-08-08 2005-02-17 Ube Industries, Ltd. アルキニル基置換縮合ヘテロ環化合物及びその製法並びにそれを使用する有機エレクトロルミネッセンス素子
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008124300A1 (en) * 2007-04-10 2008-10-16 National Health Research Institutes Hepatitis c virus inhibitors
US7897764B2 (en) * 2007-06-08 2011-03-01 National Health Research Institutes Thiourea derivatives
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997542A (en) * 1975-06-23 1976-12-14 Sterling Drug Inc. 1-(Halogenated-acetyl)-1,2,3,4-tetrahydro-6-quinolinols and esters thereof
NZ227042A (en) 1987-11-27 1991-05-28 Banyu Pharma Co Ltd Substituted alkylamine derivatives and pharmaceutical compositions
US5288749A (en) 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
TW438774B (en) 1993-07-14 2001-06-07 Hoffmann La Roche Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines
JP2000504336A (ja) 1996-02-02 2000-04-11 ゼネカ・リミテッド 薬学製剤として有用なヘテロ環式化合物
DE19727117A1 (de) 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist

Also Published As

Publication number Publication date
JP4068459B2 (ja) 2008-03-26
KR20030063453A (ko) 2003-07-28
MXPA03005395A (es) 2003-09-25
BR0116263A (pt) 2003-12-30
CN1208322C (zh) 2005-06-29
EP1358162B1 (en) 2006-02-08
US7102007B2 (en) 2006-09-05
ZA200304646B (en) 2004-09-13
CA2431100A1 (en) 2002-06-27
CN1481366A (zh) 2004-03-10
JP2004519441A (ja) 2004-07-02
AU2002219176B2 (en) 2006-02-09
DE60117096D1 (de) 2006-04-20
EP1358162A1 (en) 2003-11-05
ES2257381T3 (es) 2006-08-01
US20030004156A1 (en) 2003-01-02
WO2002050041A1 (en) 2002-06-27
AU1917602A (en) 2002-07-01
ATE317386T1 (de) 2006-02-15
CA2431100C (en) 2009-03-24
US6706751B2 (en) 2004-03-16
US20050020624A1 (en) 2005-01-27
KR100530408B1 (ko) 2005-11-22
DE60117096T2 (de) 2006-11-23

Similar Documents

Publication Publication Date Title
EA200500814A1 (ru) Производные пирролопиримидина
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
MY139446A (en) Novel quinoline derivatives
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
TW200607807A (en) Macrocyclic beta-secretase inhibitors
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
TR200102136T2 (tr) Antikanser maddeleri olarak faydaı ikame-edilmiş bisiklik türevler.
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
TW200621249A (en) Substituted amide beta secretase inhibitors
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
ES2191260T3 (es) Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
AR063118A1 (es) Derivados de sulfonamida-piperidina composiciones farmaceuticas que los contienen y usos en enfermedades y trastornos inflamatorios alergicos y respiratorios
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
BR0311535A (pt) Uso de cianopirrolidinas substituìdas e preparações de combinações contendo as mesmas para o tratamento da hiperlipidemia e doenças associadas
AR045694A1 (es) Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion
AR035408A1 (es) Compuestos derivados de dihidroindol y tetrahidroquinoleina, su empleo, un procedimiento para fabricarlos y composiciones farmaceuticas que los comprenden
EA202190245A1 (ru) Производные спирохромана
PT649846E (pt) Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos
PA8525101A1 (es) Nuevos derivados de aminociclohexanol
EA200900582A1 (ru) Фармацевтические композиции для профилактики и лечения глазных патологий

Legal Events

Date Code Title Description
FB Suspension of granting procedure